Obesity differs from diabetes mellitus in antibody and T-cell responses post-COVID-19 recovery

Archive ouverte

Ali, Mohammad | Longet, Stephanie | Neale, Isabel | Rongkard, Patpong | Chowdhury, Forhad Uddin Hassan | Hill, Jennifer | Brown, Anthony | Laidlaw, Stephen | Tipton, Tom | Hoque, Ashraful | Hassan, Nazia | Hackstein, Carl-Philipp | Adele, Sandra | Akther, Hossain Delowar | Abraham, Priyanka | Paul, Shrebash | Rahman, Md Matiur | Alam, Md Masum | Parvin, Shamima | Mollah, Forhadul Hoque | Hoque, Md Mozammel | Moore, Shona | Biswas, Subrata | Turtle, Lance | de Silva, Thushan | Ogbe, Ane | Frater, John | Barnes, Eleanor | Tomic, Adriana | Carroll, Miles | Klenerman, Paul | Kronsteiner, Barbara | Chowdhury, Fazle Rabbi | Dunachie, Susanna

Edité par CCSD ; Wiley -

International audience. Abstract Objective: Obesity and type 2 diabetes (DM) are risk factors for severe coronavirus disease 2019 (COVID-19) outcomes, which disproportionately affect South Asian populations. This study aims to investigate the humoral and cellular immune responses to SARS-CoV-2 in adult COVID-19 survivors with overweight/obesity (Ov/Ob, BMI ≥ 23 kg/m2) and DM in Bangladesh. Methods: In this cross-sectional study, SARS-CoV-2-specific antibody and T-cell responses were investigated in 63 healthy and 75 PCR-confirmed COVID-19 recovered individuals in Bangladesh, during the pre-vaccination first wave of the COVID-19 pandemic in 2020. Results: In COVID-19 survivors, SARS-CoV-2 infection induced robust antibody and T-cell responses, which correlated with disease severity. After adjusting for age, sex, DM status, disease severity, and time since onset of symptoms, Ov/Ob was associated with decreased neutralizing antibody titers, and increased SARS-CoV-2 spike-specific IFN-γ response along with increased proliferation and IL-2 production by CD8 + T cells. In contrast, DM was not associated with SARS-CoV-2-specific antibody and T-cell responses after adjustment for obesity and other confounders. Conclusion: Ov/Ob is associated with lower neutralizing antibody levels and higher T-cell responses to SARS-CoV-2 post-COVID-19 recovery, while antibody or T-cell responses remain unaltered in DM.

Consulter en ligne

Suggestions

Du même auteur

Immunogenicity of COVID ‐19 vaccines in patients with follicular lymphoma receiving frontline chemoimmunotherapy

Archive ouverte | Lim, Yeong Jer | CCSD

International audience. Summary Immune responses to primary COVID‐19 vaccination were investigated in 58 patients with follicular lymphoma (FL) as part of the PETReA trial of frontline therapy (EudraCT 2016–004010‐1...

Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trial

Archive ouverte | Goodyear, Carl | CCSD

International audience

SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses

Archive ouverte | Dejnirattisai, Wanwisa | CCSD

International audience

Chargement des enrichissements...